<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        26-7-83
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1983
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOLVADEX 10 MG TABs
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TAMOXIFEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        242.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AstraZeneca" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Nolvadex is used to treat breast cancer.</li><li>It is also used to treat infertility in women caused by a failure to produce and release eggs (ovulate) properly.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nolvadex contains a medicine called tamoxifen. This belongs to a group of medicines called &lsquo;anti-oestrogens&rsquo;.<br />Oestrogen is a natural substance in your body known as a &lsquo;sex hormone&rsquo;. Nolvadex works by blocking the effects of oestrogen.<br />&bull; Nolvadex is used to treat breast cancer.<br />&bull; It is also used to treat infertility in women caused by a failure to produce and release eggs (ovulate) properly.<br /><strong>Before taking your medicine:</strong><br /><strong>Do not take Nolvadex:</strong><br />If you are allergic to tamoxifen or any of the other ingredients of this medicine<br /><strong>Take special care:</strong></p><p>Co-administration with the following drugs should be avoided because a reduction of<br />the effect of tamoxifen cannot be excluded: paroxetine, fluoxetine (e.g.<br />antidepressants), bupropion (antidepressant or aid to smoking cessation), quinidine (for example used in the treatment of cardiac arrhythmia) and cincalet/cinacalcet (for treatment of disorders of the parathyroid gland).<br />In delayed breast reconstruction operation (weeks to years after the primary breast operation when your own tissue is moved to shape a new breast) Nolvadex may increase the risk of the formation of blood clots in the small vessels of the tissue flap which may lead to complications.</p><p><strong>Taking other medicines:</strong><br />Please inform your doctor if you are taking, or have recently taken any other medicines, even those you have bought without prescription. In particular, you should inform your doctor if you are taking:<br />&bull; paroxetine, fluoxetine (e.g. antidepressants).<br />&bull; bupropion (antidepressant or aid to smoking cessation).<br />&bull; quinidine (for example used in the treatment of cardiac arrhythmia).<br />&bull; cinacalcet (for treatment of disorders of the parathyroid gland).<br />&bull; Are you pregnant?<br />&bull; Are you breast-feeding?<br />&bull; Are you taking any anticoagulant tablets?<br />&bull; Have you ever had an allergic reaction to Nolvadex, or to any of its ingredients?<br />&bull; Do you or your family have a history of blood clots or a known inherited condition leading to an increased risk of clotting?<br />If the answer is yes to any of these questions, tell your doctor or pharmacist. Nolvadex should not be taken by women who are pregnant or breast-feeding and it can also interact with certain types of anticoagulant medicine, and a drug called rifampicin (for tuberculosis). Nolvadex should not be taken with aromatase inhibitors such as anastrozole, letrozole or exemestane.</p><p>You should not become pregnant when taking Nolvadex. Please see your doctor for<br />advice on what contraceptive precautions you should take, as some may be affected<br />by Nolvadex. You should see your doctor immediately if you think you may have become pregnant after starting to take Nolvadex.<br />Nolvadex tablets contain lactose and titanium dioxide. These may cause a problem in a small number of people who are sensitive to them.<br /><br /><br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Taking your medicine:</strong><br />Follow your doctor&rsquo;s instructions about when and how to take your medicine. Also read the label. Your pharmacist can also help if you are not sure.<br />The usual dosage to treat breast cancer is 20 mg daily. The daily dose can either be taken as a single dose every day or the dose can be divided in two and taken in the morning and evening.<br />The dosage for infertility depends on the menstrual cycle. In women who are having regular periods, treatment usually begins by taking 20 mg of Nolvadex daily on the second, third, fourth and fifth days of the menstrual cycle. If this is not successful, your doctor may increase the dosage on these days to 40 mg or 80 mg daily. In women<br />who are not having regular periods, the treatment can be started on any day.<br />If you forget to take a dose, take it as soon as you remember and then carry on as before.<br />If you are to undergo planned surgery, you should tell your doctor or pharmacist as they may wish to consider stopping your treatment for a short period.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>After taking your medicine:</strong></p><p>As with all medicines, undesirable events can sometimes be experienced with Nolvadex. Occasionally, a few people can suffer from stomach or gut upsets (including nausea, vomiting, diarrhoea and constipation), headaches, light-headedness, sensory changes (including taste disorder and numbness or tingling in the skin), menstrual disturbances, hot flushes, genital itching, vaginal discharge or bleeding, fluid retention, leg cramps, muscle pain, hypertriglyceridemia (increased levels of fats in your blood) sometimes with pancreatitis (pain or tenderness in your upper abdomen), skin rashes or itching or peeling skin, thinning of the hair, or inflammation of the lungs (which may<br />present with the same symptoms as pneumonia, such as breathlessness and cough).<br />Other possible events are changes in vision or difficulty seeing properly as a result of cataracts or changes to the cornea or retina. Cases of optic nerve diseases have been reported in patients receiving tamoxifen and, in a small number of cases, blindness has occurred. Other possible events are an increased risk of blood clots (including clots in small vessels), ovarian cysts, certain liver problems such as jaundice and changes in blood tests of liver function. On occasions more severe liver diseases have occurred from which some patients have died. These liver diseases include inflammation of the liver, liver cirrhosis, liver cell damage, formation of fatty liver cells, reduced bile formation, and failure of the liver. Symptoms may include a general feeling of being unwell, with or without jaundice (yellowing of the skin and eyes). Other possible events are effects on the endometrium (lining of the womb) which may also be seen as vaginal bleeding, or fibroids (causes enlargement of the womb) which may also be seen as discomfort in the pelvis or as vaginal bleeding.</p><p>Cases of non-cancerous mass in the inner lining of the vagina (called vaginal polyps)<br />have been reported, but are uncommon. Some side effects are only seen when a<br />blood test is taken such as a decrease in the number of certain types of blood cells. This can make you bruise more easily, get serious infections, or feel very tired or breathless. Sudden onset of weakness or paralysis of the arms or legs, sudden difficulty with speaking, walking, difficulty in holding things or difficulty in thinking, any of which may occur because the blood supply in the blood vessels of the brain is reduced. These symptoms could be signs of a stroke. Very rarely, cases of inflammation of the skin characterised by rash or erythema, very often on areas exposed to light (a condition called cutaneous lupus erythematosus) and cases of a skin condition characterised by skin blisters in areas exposed to the light, this is due to the increased liver production of a special group of cell pigments (called porphyrins), have been reported.<br />It is important that you tell your doctor immediately if you have any unusual vaginal bleeding, vaginal discharge or discomfort in the pelvis such as pain or pressure when you are taking Nolvadex or anytime afterwards. This is because a number of changes to the lining of the womb (the endometrium) may occur, some of which may be serious and could include cancer.<br />At the beginning of treatment for breast cancer, the symptoms of the disease can sometimes get worse, for example an increase in pain or an increase in the size of the affected tissue. In addition, if you get excessive nausea, vomiting or thirst, tell your doctor because this may mean that there are changes in the amount of calcium in your blood and your doctor may want to check on this.<br />Do not be alarmed by this list of possible events. You may not have any of them.<br />If you get any other undesirable events or if you think your medicine is causing any problems, tell your doctor or pharmacist.</p><p><strong>STOP TAKING Nolvadex and contact your doctor immediately in any of the following situations:</strong><br />&bull; If you develop symptoms of a blood clot such as calf or leg swelling, chest pain, shortness of breath or sudden weakness.<br />&bull; If you develop difficulty in breathing with or without swelling of the face, lips, tongue and/or throat.<br />&bull; If you develop swelling of the face, lips, tongue and/or throat which may cause<br />difficulty swallowing.<br />&bull; If you develop swelling of the hands, feet or ankles.<br />&bull; If you develop urticaria (nettle rash or hives).<br />If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep your medicine in a safe place where children cannot see it or reach it. Your medicine could harm them.</p><p>- Keep your medicine below 30<sup>o</sup>C<br />- Keep your tablets in the container they came in (away from strong light).<br />- Check the expiry date on the carton and don&rsquo;t use the medicine after that date.<br />- If your doctor decides to stop treatment, return any leftover tablets to your pharmacist. Only keep them if the doctor tells you to.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is Nolvadex. The active ingredient is tamoxifen. Your medicine also contains the following inactive ingredients: croscarmellose sodium, gelatin, lactose, macrogol, magnesium stearate, maize starch, methylhydroxypropylcellulose and titanium dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Nolvadex tablets contain 10 mg of tamoxifen. Nolvadex tablets are produced in packs of 30.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorisation for Nolvadex is held by AstraZeneca UK Limited, 600<br />Capability Green, Luton, LU1 3LU, UK. Nolvadex is manufactured by AstraZeneca<br />UK Limited, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, UK.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                February 2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>&bull; يستخدم نولفادكس في علاج سرطان الثدي.</p><p>&bull; ويستخدم كذلك في علاج العقم لدى النساء الناتج عن قصور إنتاج وإطلاق البويضات (التبييض)</p><p>بشكل مناسب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>يحتوي نولفادكس على دواء يسمى تاموكسيفين. تنتمي هذا المادة إلى مجموعة من الأدوية يُطلق عليها</p><p>&quot;الأدوية المضادة للاستروجين &quot; .</p><p>الاستروجين هو مادة طبيعية بالجسم تعرف ب&quot;الهرمون الجنسي&quot;. يعمل نولفادكس عبر إحصار تأثير</p><p>الاستروجين.</p><p>&bull; يستخدم نولفادكس في علاج سرطان الثدي.</p><p>&bull; ويستخدم كذلك في علاج العقم لدى النساء الناتج عن قصور إنتاج وإطلاق البويضات (التبييض)</p><p>بشكل مناسب.</p><p>&nbsp;</p><p><strong>قبل تناول الدواء :<br />لا تتناولي نولفادكس :</strong><br />إذا كانت لديكِ حساسية(فرط حساسية) تجاه تاموكسيفين أو أي من المكونات الأخرى للدواء.<br /><strong>توخي الحرص الشديد :</strong><br />يجب تجنب التناول المتزامن للأدوية التالية وذلك بسبب عدم استبعاد تقليل تأثير تاموكسيفين: باروكستين<br />وفلوكستين(مثل مضادات الاكتئاب) وبوبربيون (مضاد اكتئاب أو مساعد على إيقاف التدخين) وكينيدين<br />(على سبيل المثال يستخدم في علاج رجفان القلب) وسيناكالت/سيناكالسيت (لعلاج اضطرابات غدد<br />جارات الدرقية).</p><p>في حالة تأخر عملية ترميم الثدي (عدة أسابيع إلى عام بعد عملية الثدي الأساسية عند نقل بعض<br />الأنسجة لزراعة ثدي جديد)، قد يزيد نولفادكس من مخاطر تكون جلطات الدم في الأوعية الصغيرة<br />في سديلة النسيج وهو ما يؤدي إلى حدوث مضاعفات.</p><p><br />تناول أدوية أخرى :<br />يُرجى إبلاغ الطبيب إذا كنتِ تتناولين أو تناولتِ مؤخرًا أي أدوية أخرى حتى تلك الأدوية التي تشترينها<br />دون وصفة طبية. يجب عليكِ بشكل خاص إبلاغ الطبيب إذا كنتِ تناولتِ ما يلي:<br />&bull; باروكستين، فلوكستين (على سبيل المثال مضادات الاكتئاب)<br />&bull; بوبروبيون (مضاد للاكتئاب أو يستخدم في المساعدة على إيقاف التدخين)<br />&bull; كينيدين (على سبيل المثال يستخدم في علاج رجفان القلب)<br />&bull; سيناكالسيت (يستخدم في علاج اضطرابات غدد جارات الدرقية)<br />&bull; هل أنتِ حامل؟<br />&bull; هل تقومين بالرضاعة؟<br />&bull; هل تتناولي أي أقراص مضادة للتخثر؟<br />&bull; هل عانيتِ يومًا من حالة تفاعل تحسّسي لعقار نولفادكس أو أي من مكوناته؟<br />&bull; هل عانيتِ أنتِ أو أسرتك من تاريخ مرضي من جلطات الدم أو من حالة وراثية معروفة تؤدي إلى<br />زيادة خطر التجلط؟<br />إذا أجبتِ بإجابة نعم على أي من تلك الأسئلة، فأخبري الطبيب أو الصيدلي. يجب تجنب تناول نولفادكس<br />من جانب النساء الحوامل أو المرضعات وقد يتفاعل الدواء مع أنواع محددة من أدوية مضادات التخثر<br />ودواء يسمى ريفامبيسين (يستخدم في علاج السل). يجب تجنب تناول نولفادكس مع مضادات أروماتيز<br />مثل أناستروزول أو ليتروزول أو إكسيميستان.<br />يجب تجنب الحمل عند تناول نولفادكس. يُرجى الرجوع للطبيب لطلب نصيحة حول احتياطات منع الحمل<br />التي يجب إتباعها حيث قد يتأثر بعضها بنولفادكس. يجب الرجوع للطبيب على الفور إذا كنتِ تعتزمين<br />الحمل بعد بدء تناول نولفادكس.<br />تحتوي أقراص نولفادكس على لاكتوز وثاني أكسيد التيتانيوم. وقد تسبب مشكلة في عدد بسيط من<br />الأشخاص ممن لديهم حساسية منها.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>اتبعي إرشادات الطبيب ذات الصلة حول توقيت وكيفية تناول نولفادكس. ويجب كذلك قراءة الملصق.</p><p>يمكن أن يقدم الصيدلي المساعدة في حال لم تكوني متأكدةً.</p><p>الجرعة المعتادة لعلاج سرطان الثدي هي 20 ملجم يوميًا. يمكن تناول الجرعة اليومية كجرعة مفردة</p><p>في كل يوم أو يمكن تقسيمها إلى مرتين وتؤخذ في الصباح والمساء.</p><p>تعتمد الجرعة الخاصة بالعقم على دورة الطمث. بالنسبة للنساء ممن تنتظم فترة الطمث لديهم، يبدأ</p><p>العلاج بتناول نولفادكس 20 ملجم يوميًا في اليوم الثاني والثالث والرابع والخامس من دورة الطمث. إذا</p><p>&nbsp;</p><p>لم يكن هذا ناجحًا، فقد يزيد الطبيب من الجرعة في هذه الأيام إلى نولفادكس 40 ملجم أو 80 ملجم</p><p>يوميًا. أما النساء ممن لا تنتظم فترة الطمث لديهم، يمكن بدء العلاج في أي يوم.</p><p>في حالة نسيان أخذ الجرعة، ينبغي تناولها بمجرد التذكر ثم المواظبة على تناولها كالسابق.</p><p>في حالةِ اعتزامكِ الخضوع لجراحة، ينبغي عليكِ إبلاغ طبيبكِ أو الصيدلي حيث قد يقرر إيقاف العلاج</p><p>لفترة بسيطة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><strong>توقفي عن تناول نولفادكس واتصلي بالطبيب على الفور في أي من الحالات التالية:</strong></p><p>&bull; إذا ظهرت أعراض جلطة دموية مثل ربلة الساق أو تورم الساق أو ألم الصدر أو ضيق التنفس أو</p><p>الضعف المفاجئ.</p><p>&bull; إذا ظهرت أعراض صعوبات في التنفس سواء تورم الوجه و/أو الشفتين و/أو اللسان و/أو الحلق أم</p><p>لا.</p><p>&bull; إذا ظهرت أعراض تورم الوجه و/أو الشفتين و/أو اللسان و/أو الحلق، والذي قد يؤدي إلى صعوبة في</p><p>البلع.</p><p>&bull; إذا ظهرت أعراض تورم اليدين أو القدمين أو الكاحلين.</p><p>&bull; إذا ظهرت أعراض الشري (شري أو حمى قراصية).</p><p>إذا كانت لديكِ أي أسئلة أخرى حول استخدام هذا الدواء، فتحدثي إلى طبيبك أو الصيدلي أو الممرضة.</p><p>بعد تناول الدواء :<br />كما هو الحال في كل الأدوية، يمكن الشعور ببعض الآثار غير المرغوب فيها عند تناول نولفادكس.<br />وبالمناسبة قد يعاني عدد قليل من الأشخاص من اضطرابات في المعدة أو الأمعاء )يشمل الغثيان<br />والتقيؤ والإسهال والإمساك( أو الصداع أو الدوار أو تغيرات عصبية )يشمل اضطراب حاسة التذوق أو<br />التنميل أو الشعور بوخز في الجلد( أو اضطرابات الدورة الشهرية أو نوبات الحرارة أو حكة الأعضاء<br />التناسلية أو الإفراز المهبلي أو النزيف أو احتباس السوائل أو تشنج الساق أو ألم العضلات أو فرط ثلاثي<br />جليسريد الدم )زيادة مستويات الدهون في الدم( أو أحيانًا يكون مصاحبًا لالتهاب البنكرياس (ألم أو عجز<br />في الجزء العلوي من البطن) أو طفح جلدي أو الحكة في الجلد أو تقشره أو سقوط الشعر أو التهاب<br />الرئتين (الذي قد يكون مصاحبًا لنفس أعراض الالتهاب الرئوي مثل صعوبة التنفس والسعال).<br />الآثار الأخرى المحتملة هي تغيرات في الرؤية أو صعوبة في الرؤية بشكل مناسب كنتيجة للمياه البيضاء<br />أو تغيرات على القرنية أو الشبكية. تم تسجيل حالات اعتلال بالعصب البصري عند المرضى الذين<br />يتناولون تاموكسيفين، كما حدثت حالات فقدان للبصر في عدد قليل من الحالات. الآثار المحتملة الأخرى<br />هي زيادة مخاطر تجلط الدم (يشمل تكون الجلطات في الأوعية الصغيرة) وتكيس المبايض ومشكلات<br />محددة في الكبد مثل اليرقان وتغيرات في اختبارات الدم عند إجراء اختبار وظائف الكبد. في بعض<br />الحالات حدثت مضاعفات حادة في أمراض الكبد ومن بين المرضى من توفي. تشمل أمراض الكبد<br />التهاب الكبد والأيض الكبدي وتضرر خلايا الكبد وتكون خلايا دهنية على الكبد وتقليل تكون الصفراء<br />والفشل الكبدي. قد تشمل الأعراض شعورًا عامًا بالتعب مع اليرقان أو بدونه (اصفرار الجلد والعين).<br />الآثار المحتملة الأخرى تكون على بطانة الرحم (ترقق الرحم) وهو ما يمكن التعرف عليه من خلال<br />النزيف المهبلي أو الليف (حالات تضخم الرحم)&nbsp;والذي يمكن التعرف عليه من خلال ألم عظام الحوض<br />أو النزيف المهبلي. في بعض الحالات ظهرت أعراض كتل الأورام غير السرطانية في بطانة الرحم<br />الداخلية (يسمى سلائل مهبلية) ولكنها غير شائعة. يمكن التعرف على بعض الآثار الجانبية فقط عند<br />إجراء اختبار للدم مثل نقص عدد أنواع خلايا دم محددة. وقد يجعلك هذا تصابين بالكدمات بسهولة<br />والإصابة بعدوى خطرة أو الشعور بالتعب الشديد أو صعوبة التنفس. الضعف المفاجئ أو شلل الأذرع<br />أو الساقين وصعوبة مفاجئة في التحدث أو السير أو صعوبة الإمساك بالأشياء أو صعوبة في التفكير<br />وقد يحدث أي منها بسبب نقص إمداد الدم في الأوعية الدموية بالمخ. يمكن أن تكون هذه الأعراض<br />إشارات للإصابة بسكتة دماغية. تم الإبلاغ عن حالات نادرة جدًا، حالات التهاب الجلد وأعراضها الطفح<br />الجلدي أو الحمامي، في أحيان كثيرة في المناطق المعرضة للضوء (حالة تعرف بالذئبة الحمامية<br />الجلدية) وحالات أمراض الجلد وأعراضها ظهور بثور على الجلد في المناطق المعرضة للضوء ويرجع<br />ذلك إلى الزيادة الكبيرة من الكبد لمجموعة خاصة من الخلايا الصبغية (يسمى البرفيرية).<br />من الهام أن تخبري الطبيب على الفور في حالة الشعور بالنزيف المهبلي غير المعتاد أو إفراز مهبلي أو<br />ألم الحوض كالشعور بالضغط في منطقة الحوض عند تناول نولفادكس أو في أي مرة بعد ذلك. وهذا<br />بسبب إمكانية حدوث بعض التغيرات على بطانة الرحم (بطانة الرحم)، قد تكون بعضها خطرة وقد<br />تشمل السرطان.<br />عند بدء علاج سرطان الثدي، قد تسوء الأعراض في بعض الأحيان مث لا زيادة الألم وزيادة حجم النسيج<br />المصاب. إضافة إلى ذلك فإذا عانيت من غثيان متزايد أو عطش متزايد، فأخبري الطبيب لأن هذا قد يعني<br />وجود تغييرات في كمية الكالسيوم في الدم وقد يرغب الطبيب في التحقق من ذلك.<br />لا تنزعجي من قائمة الآثار الجانبية هذه. فقد لا تصابي بأي منها.<br />إذا أصبتِ بأي من الآثار الأخرى غير المرغوبة أو إذا كنت تعتقدين أن هذا الدواء يسبب أية مشكلات،<br />فأخبري الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>- احتفظي بالدواء في مكان آمن، بعيدًا عن متناول الأطفال ورؤيتهم. إذ قد يضرهم تناول الدواء.</p><p>- احتفظي بالدواء في درجة حرارة أقل من 30 درجة مئوية.</p><p>- احتفظي بالأقراص داخل حاويتها الأصلية )بعيدًا عن الضوء الشديد(.</p><p>- تحققي من تاريخ انتهاء الصلاحية المدون على العبوة الورقية ولا تستخدم الدواء بعد هذا</p><p>التاريخ.</p><p>- إذا قرر الطبيب إيقاف العلاج، فأعيدي الأقراص المتبقية إلى الصيدلي. فقط احتفظي بها إذا</p><p>أخبرك الطبيب بذلك.</p><p>لا تتخلصي من الأدوية بإلقائها في مياه الصرف الصحي أو النفايات المنزلية. اسألي الصيدلي الخاص</p><p>بك عن إجراءات التخلص من الأدوية التي لم تعودي تستعملينها. حيث تساعد هذه الإجراءات في</p><p>حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>اسم الدواء هو نولفادكس. المكون النشط هو تاموكسيفين. يحتوي الدواء كذلك على المكونات النشطة</p><p>التالية: كروس كارميلوز الصوديوم وجيلاتين و لاكتوز وماكروجل وسترات الماغنسيوم ونشا الذرة وميثيل</p><p>هيدروكسي بروبيل سليولوز وثاني أكسيد التيتانيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تحتوي أقراص نولفادكس على 10 ملجم من تاموكسيفين.
يتم إنتاج أقراص نولفادكس في عبوات تحتوي على 30 قرصًا.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>تراخيص التسويق لعقار نولفادكس مملوكة لشركة AstraZeneca المحدودة في المملكة المتحدة</p><p>والكائنة في 600 Capability Green ، Luton ، LU1 3LU ، UK . يتم تصنيع نولفادكس من خلال شركة</p><p>AstraZeneca المحدودة في المملكة المتحدة Silk Road Business Park ، Macclesfield ،</p><p>Cheshire ، SK10 2NA ، المملكة المتحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nolvadex
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tamoxifen Citrate Ph. Eur. 15.2 mg (equivalent to 10 mg tamoxifen).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nolvadex is indicated for:<br />1. The treatment of breast cancer.<br />2. The treatment of anovulatory infertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Route of administration: Oral<br /><strong>1. Breast Cancer<br />Adults</strong><br />The recommended daily dose of tamoxifen is normally 20 mg. No additional benefit, in terms of delayed recurrence or improved survival in patients, has been demonstrated with higher doses. Substantive evidence supporting the use of treatment with 30&ndash;40 mg per day is not available, although these doses have been used in some patients with advanced disease.<br /><strong>Elderly patients</strong><br />Similar dosing regimens of Nolvadex have been used in elderly patients with breast cancer and in some of these patients it has been used as sole therapy.<br /><strong>2. Anovulatory Infertility</strong><br />Before commencing any course of treatment, whether initial or subsequent, the possibility of pregnancy must be excluded. In women who are menstruating regularly, but with anovular cycles, the initial course of treatment consists of 20 mg given daily on the second, third, fourth and fifth days of the menstrual cycle. If unsatisfactory basal temperature records or poor pre-ovulatory cervical mucus&nbsp;indicate that this initial course of treatment has been unsuccessful, further courses may be given during subsequent menstrual periods, increasing the dosage to 40 mg and then to 80 mg daily.<br />In women who are not menstruating regularly, the initial course may begin on any day. If no signs of ovulation are demonstrable, then a subsequent course of treatment may start 45 days later, with dosage increased as above. If a patient responds with menstruation, then the next course of treatment is commenced on the second day of the cycle.<br /><strong>Use in children</strong><br />The use of Nolvadex is not recommended in children, as safety and efficacy have not been established (see sections 5.1 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nolvadex must not be given during pregnancy. Premenopausal patients must be carefully examined before treatment for breast cancer or infertility to exclude the possibility of pregnancy (see also section 4.6).
Nolvadex should not be given to patients who have experienced hypersensitivity to the product or any of its ingredients.
Concurrent anastrozole therapy (see section 4.5).
Treatment for infertility: Patients with a personal or family history of confirmed idiopathic venous thromboembolic events or a known genetic defect.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Menstruation is suppressed in a proportion of premenopausal women receiving Nolvadex for the treatment of breast cancer.<br />An increased incidence of endometrial changes including hyperplasia, polyps, cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours), has been reported in association with Nolvadex treatment. The underlying mechanism is unknown but may be related to the oestrogen-like effect of Nolvadex. Any patient receiving or having previously received Nolvadex who report abnormal gynaecological symptoms, especially vaginal bleeding, or who presents with menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.<br />A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen. No causal link has been established and the clinical significance of these observations remains unclear.</p><p><u>Venous thromboembolism</u><br />&bull; A 2&ndash;3-fold increase in the risk for VTE has been demonstrated in healthy tamoxifen-treated women (see section 4.8).<br />&bull; In patients with breast cancer, prescribers should obtain careful histories with respect to the patient&rsquo;s personal and family history of VTE. If suggestive of a prothrombotic risk, patients should be screened for thrombophilic factors. Patients who test positive should be counselled regarding their thrombotic risk. The decision to use tamoxifen in these patients should be based on the overall risk to the patient. In selected patients, the use of tamoxifen with prophylactic anticoagulation may be justified (cross-reference section 4.5)<br />&bull; The risk of VTE is further increased by severe obesity, increasing age and all other risk factors for VTE. The risks and benefits should be carefully considered for all patients before treatment with tamoxifen. In patients with breast cancer, this risk is also increased by concomitant chemotherapy (see section 4.5). Long-term anticoagulant prophylaxis may be justified for some patients with breast cancer who have multiple risk factors for VTE.<br />&bull; Surgery and immobility: For patients being treated for infertility, tamoxifen should be stopped at least 6 weeks before surgery or long-term immobility (when possible) and re-started only when the patient is fully mobile. For patients with breast cancer, tamoxifen treatment should only be stopped if the risk of tamoxifen-induced thrombosis clearly outweighs the risks associated with interrupting treatment. All patients should receive appropriate thrombosis prophylactic measures and should include graduated compression stockings for the period of hospitalisation, early ambulation, if possible, and anticoagulant treatment.</p><p>&bull; If any patient presents with VTE, tamoxifen should be stopped immediately and appropriate anti-thrombosis measures initiated. In patients being treated for infertility, tamoxifen should not be re-started unless there is a compelling alternative explanation for their thrombotic event. In patients receiving tamoxifen for breast cancer, the decision to re-start tamoxifen should be made with respect to the overall risk for the patient. In selected patients with breast cancer, the continued use of tamoxifen with prophylactic anticoagulation may be justified.<br />&bull; All patients should be advised to contact their doctors immediately if they become aware of any symptoms of VTE.<br />In delayed microsurgical breast reconstruction Nolvadex may increase the risk of microvascular flap complications.<br />In an uncontrolled trial in 28 girls aged 2&ndash;10 years with McCune Albright Syndrome (MAS), who received 20 mg once a day for up to 12 months duration,&nbsp;mean uterine volume increased after 6 months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established (see section 5.1).<br />In the literature it has been shown that CYP2D6 poor metabolisers have a lowered plasma level of endoxifen, one of the most important active metabolites of tamoxifen (see section 5.2).<br />Concomitant medications that inhibit CYP2D6 may lead to reduced concentrations of the active metabolite endoxifen. Therefore, potent inhibitors of CYP2D6 (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided during tamoxifen treatment (see section 4.5 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When Nolvadex is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such co-administration is initiated, careful monitoring of the patient is recommended.<br />When Nolvadex is used in combination with cytotoxic agents for the treatment of breast cancer, there is increased risk of thromboembolic events occurring. (See also sections 4.4 and 4.8). Because of this increase in risk of VTE, thrombosis prophylaxis should be considered for these patients for the period of concomitant chemotherapy.<br />The use of tamoxifen in combination with anastrozole as adjuvant therapy has not shown improved efficacy compared with tamoxifen alone.<br />As Nolvadex is metabolised by cytochrome P450 3A4, care is required when co-administering with drugs, such as rifampicin, known to induce this enzyme as tamoxifen levels may be reduced. The clinical relevance of this reduction is unknown.<br />Pharmacokinetic interaction with CYP2D6 inhibitors, showing a reduction in plasma level of an active tamoxifen metabolite, 4-hydroxy-N-desmethyltamoxifen (endoxifen), has been reported in the literature.<br />Pharmacokinetic interaction with CYP2D6 inhibitors, showing a 65-75% reduction in plasma levels of one of the more active forms of the drug, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants (e.g. paroxetine) in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, quinidine, cinacalcet or bupropion) should whenever possible be avoided (see section 4.4 and 5.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br />Nolvadex must not be administered during pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and foetal deaths after women have taken Nolvadex, although no causal relationship has been established.<br />Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential.<br />In rodent models of foetal reproductive tract development, tamoxifen was associated with changes similar to those caused by estradiol, ethinylestradiol, clomiphene and diethylstilboestrol (DES). Although the clinical relevance of these changes is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES in utero and who have a 1 in 1000 risk of developing clear-cell carcinoma of the vagina or cervix. Only a small number of pregnant women have been exposed to tamoxifen. Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed in utero to tamoxifen.<br />Women should be advised not to become pregnant whilst taking Nolvadex and should use barrier or other non-hormonal contraceptive methods if sexually active. Premenopausal patients must be carefully examined before treatment to exclude pregnancy. Women should be informed of the potential risks to the foetus, should they become pregnant whilst taking Nolvadex or within two months of cessation of therapy.</p><p><strong>Lactation</strong><br />It is not known if Nolvadex is excreted in human milk and therefore the drug is not recommended during lactation. The decision either to discontinue nursing or discontinue Nolvadex should take into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that Nolvadex results in impairment of these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unless specified, the following frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9366 postmenopausal women patients with operable breast cancer treated for 5 years and unless specified, no account was taken of the frequency within the comparative treatment group or whether the investigator considered it to be related to study medication.</p><p><strong>Table 1&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp;Adverse Drug Reactions (ADR) seen with Nolvadex</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:1031px"><tbody><tr><td style="width:291px"><strong>Frequency</strong></td><td style="width:460px"><strong>System Organ Class (SOC)</strong></td><td style="width:278px"><strong>ADR</strong></td></tr><tr><td style="width:291px">Very common<br />(&ge;10%)</td><td style="width:460px"><p>Gastrointestinal disorders</p><p>Metabolism and nutrition</p><p>Reproductive system and breast</p><p>Skin and subcutaneous tissue</p><p>Vascular</p></td><td style="width:278px"><p>&bull; Nausea</p><p>&bull; Fluid retention</p><p>&bull; Vaginal bleeding<br />&bull; Vaginal discharge</p><p>&bull; Skin Rash</p><p>&bull; Hot flushes</p></td></tr><tr><td style="width:291px">Common<br />(&ge;1% and &lt;10%)</td><td style="width:460px"><p>Blood and lymphatic system</p><p>Eye disorders</p><p>Immune system disorders</p><p>Investigations</p><p>Musculoskeletal and connective tissue</p><p>Neoplasms benign, malignant and unspecified</p><p>Nervous system</p><p>Reproductive system and breast</p><p>Skin and subcutaneous tissue</p><p>Gastrointestinal disorders</p><p>Hepatobiliary disorders</p><p>Multiple SOC Terms</p></td><td style="width:278px"><p>&bull; Anaemia</p><p>&bull; Cataracts<br />&bull; Retinopathy</p><p>&bull; Hypersensitivity reactions</p><p>&bull; Elevated triglycerides</p><p>&bull; Leg cramp<br />&bull; Myalgia</p><p>&bull; Uterine fibroids</p><p>&bull; Ischaemic cerebrovascular events<br />&bull; Headache<br />&bull; Light headedness<br />&bull; Sensory disturbances (including paraesthesia and dysgeusia)</p><p>&bull; Pruritus valvae<br />&bull; Endometrial changes (including hyperplasia and polyps)</p><p>&bull; Alopecia</p><p>&bull; Vomiting<br />&bull; Diarrhoea<br />&bull; Constipation</p><p>&bull; Changes in liver enzymes</p><p>&bull; Fatty liver</p><p>&bull; Thromboembolic events (including deep vein thrombosis, microvascular thrombosis and pulmonary embolism)</p></td></tr><tr><td style="width:291px">Uncommon<br />(&ge; 0.1% and &lt;1%)</td><td style="width:460px"><p>Blood and lymphatic system</p><p>Eye disorders</p><p>Gastrointestinal disorders</p><p>Metabolism and nutrition</p><p>Neoplasms benign, malignant and unspecified</p><p>Respiratory, thoracic and mediastinal disorders</p><p>Hepatobiliary disorders</p></td><td style="width:278px"><p>&bull; Thrombocytopenia<br />&bull; Leukopenia</p><p>&bull; Visual disturbances</p><p>&bull; Pancreatitis</p><p>&bull; Hypercalcaemia (in patients with bony metastases)</p><p>&bull; Endometrial cancer</p><p>&bull; Interstitial pneumonitis</p><p>&bull; Cirrhosis of the liver</p></td></tr><tr><td style="width:291px">Rare<br />(&ge; 0.01% and &lt;0.1%)</td><td style="width:460px"><p>Blood and lymphatic system disorders</p><p>Eye disorders</p><p>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</p><p>Nervous system</p><p>Hepatobiliary disorders</p><p>Skin and subcutaneous tissue</p></td><td style="width:278px"><p>&bull; Neutropenia<sup>a</sup><br />&bull; Agranulocytosis<sup>a</sup></p><p>&bull; Corneal changes<br />&bull; Optic neuropathy<sup>a</sup></p><p>&bull; Uterine Sarcoma (mostly malignant mixed Mullerian tumours)<sup>a</sup><br />&bull; Tumour Flare<sup>a</sup></p><p>&bull; Optic neuritis</p><p>&bull; Hepatitis<br />&bull; Cholestasis<sup>a</sup><br />&bull; Hepatic failure<sup>a</sup><br />&bull; Hepatocellular injury<sup>a</sup><br />&bull; Hepatic necrosis<sup>a</sup></p><p>&bull; Angioedema<br />&bull; Steven-Johnsons syndrome<sup>a</sup></p></td></tr><tr><td style="width:291px">Very Rare<br />(&lt;0.01%)</td><td style="width:460px"><p>Reproductive system and breast disorders</p><p>&nbsp;</p><p>&nbsp;</p><p>Skin and subcutaneous tissue</p><p>&nbsp;</p><p>Congenital, familial and genetic disorders</p></td><td style="width:278px"><p>&bull; Cutaneous vasculitis<sup>a</sup><br />&bull; Bullous pemphigoid<sup>a</sup><br />&bull; Erythema multiforme<sup>a</sup><br />Reproductive system and breast disorders<br />&bull; Endometriosis<sup>a</sup><br />&bull; Cystic ovarian swelling<sup>a</sup><br />&bull; Vaginal polyps</p><p>&bull; Cutaneous lupus erythematosus<sup>b</sup></p><p>&nbsp;</p><p>&bull; Porphyria cutanea tarda<sup>b</sup></p></td></tr></tbody></table><p><sup>a</sup> This adverse drug reaction was not reported in the tamoxifen arm (n= 3094) of the above study; however, it has been reported in other trials or from other sources. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size e.g. 3094). This is calculated as 3/3094 which equates to a frequency category of &lsquo;rare&rsquo;.<br />b The event was not observed in other major clinical studies. The frequency has been calculated using the<br />upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size of 13,357 patients in the major clinical studies). This is calculated as 3/13,357 which equates to a frequency category of &lsquo;very rare&rsquo;.</p><p>Side effects can be classified as either due to the pharmacological action of the drug, e.g. hot flushes, vaginal bleeding, vaginal discharge, pruritus vulvae and tumour flare, or as more general side effects, e.g. gastrointestinal intolerance, headache, light-headedness and occasionally, fluid retention and alopecia.<br />When side effects are severe, it may be possible to control them by a simple reduction of dosage (to not less than 20 mg/day) without loss of control of the disease. If side effects do not respond to this measure, it may be necessary to stop the treatment.<br />Skin rashes (including rare reports of erythema multiforme, Stevens-Johnson syndrome, cutaneous vasculitis, and bullous pemphigoid) and commonly hypersensitivity reactions including angioedema have been reported.<br />Uncommonly, patients with bony metastases have developed hypercalcaemia on initiation of therapy.<br />Cases of visual disturbances, including rare reports of corneal changes, and<br />common reports of retinopathy have been described in patients receiving Nolvadex<br />therapy. Cataracts have been reported commonly in association with the<br />administration of Nolvadex.</p><p>Cases of optic neuropathy and optic neuritis have been reported in patients<br />receiving tamoxifen and, in a small number of cases, blindness has occurred.<br />Sensory disturbances (including paraesthesia and dysgeusia) have been reported commonly in patients receiving Nolvadex.<br />Uterine fibroids, endometriosis and other endometrial changes including<br />hyperplasia and polyps have been reported.<br />Falls in platelet count, usually to 80,000 to 90,000 per cu mm but occasionally lower, have been reported in patients taking tamoxifen for breast cancer.<br />Leucopenia has been observed following the administration of Nolvadex, sometimes in association with anaemia and/or thrombocytopenia. Neutropenia has been reported on rare occasions; this can sometimes be severe, and very rarely cases of agranulocytosis have been reported.<br />There is evidence of ischaemic cerebrovascular events and thromboembolic events, including deep vein thrombosis, microvascular thrombosis and pulmonary embolism, occurring commonly during tamoxifen therapy (see sections 4.3, 4.4 and 4.5). When Nolvadex is used in combination with cytotoxic agents, there is an increased risk of thromboembolic events occurring.<br />Leg cramps and myalgia have been reported commonly in patients receiving Nolvadex.<br />Uncommonly, cases of interstitial pneumonitis have been reported.<br />Nolvadex has been associated with changes in liver enzyme levels and with a spectrum of more severe liver abnormalities which in some cases were fatal, including fatty liver, cholestasis and hepatitis, liver failure, cirrhosis,and, hepatocellular injury (including hepatic necrosis).<br />Commonly, elevation of serum triglyceride levels, in some cases with pancreatitis, may be associated with the use of Nolvadex.<br />Cystic ovarian swellings have rarely been observed in women receiving Nolvadex.<br />Vaginal polyps have rarely been observed in women receiving Nolvadex.<br />Cutaneous lupus erythematosus has been observed very-rarely in patients receiving Nolvadex.<br />Porphyria cutanea tarda has been observed very-rarely in patients receiving Nolvadex.</p><p>Uncommonly incidences of endometrial cancer and rare instances of uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with Nolvadex treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>On theoretical grounds, an overdosage would be expected to cause enhancement of the pharmacological side effects mentioned above. Observations in animals show that extreme overdosage (100&ndash;200 times recommended daily dose) may produce oestrogenic effects.<br />There have been reports in the literature that Nolvadex given at several times the standard dose may be associated with prolongation of the QT interval of the ECG.<br />There is no specific antidote to overdosage, and treatment must be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>displays a complex spectrum of oestrogen antagonist and oestrogen agonist-like pharmacological effects in different tissues. In breast cancer patients, at the tumour level, tamoxifen acts primarily as an antioestrogen, preventing oestrogen binding to the oestrogen receptor. In the clinical situation, it is recognised that tamoxifen leads to reductions in levels of blood total cholesterol and low density lipoproteins in postmenopausal women of the order of 10&ndash;20%. Tamoxifen does not adversely affect bone mineral density.<br />An uncontrolled trial was undertaken in a heterogenous group of 28 girls aged 2 to 10 years with McCune Albright Syndrome (MAS), who received 20 mg once a day for up to 12 months duration. Among the patients who reported vaginal bleeding during the pre-study period, 62% (13 out of 21 patients) reported no bleeding for a 6-month period and 33% (7 out of 21 patients) reported no vaginal bleeding for the duration of the trial. Mean uterine volume increased after 6 months of treatment and doubled at the end of the one-year study. While this finding is in line with the pharmacodynamic properties of tamoxifen, a causal relationship has not been established (see section 4.4). There are no long-term safety data in children. In particular, the long-term effects of tamoxifen on growth, puberty and general development have not been studied.<br />CYP2D6 polymorphism status may be associated with variability in clinical response to tamoxifen. The poor metaboliser status may be associated with reduced response. The consequences of the findings for the treatment of CYP2D6 poor metabolisers have not been fully elucidated (see sections 4.4, 4.5 and 5.2)</p><p><br /><strong>CYP2D6 genotype</strong></p><p>Available clinical data suggest that patients who are homozygote for non-functional CYP2D6 alleles, may experience reduced effect of tamoxifen in the treatment of breast cancer.<br />The available studies have mainly been performed in postmenopausal women (see sections 4.4 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration, tamoxifen is absorbed rapidly with maximum serum concentrations attained within 4&ndash;7 hours. Steady state concentrations (about 300 ng/ml) are achieved after four weeks treatment with 40 mg daily. The drug is highly protein bound to serum albumin (&gt;99%). Metabolism is by hydroxylation, demethylation and conjugation, giving rise to several metabolites which have a similar pharmacological profile to the parent compound and thus contribute to the therapeutic effect. Excretion occurs primarily via the faeces and an elimination half-life of approximately seven days has been calculated for the drug itself, whereas that for N-desmethyltamoxifen, the principal circulating metabolite, is 14 days.<br />In a clinical study where girls between 2 and 10 years with McCune Albright Syndrome (MAS) received 20 mg tamoxifen once a day for up to 12 months duration, there was an age-dependent decrease in clearance and an increase in exposure (AUC), (with values up to 50% higher in the youngest patients) compared with adults.<br />Tamoxifen is metabolised mainly via CYP3A4 to N-desmethyl-tamoxifen, which is further metabolised by CYP2D6 to another active metabolite endoxifen. In patients who lack the enzyme CYP2D6 endoxifen concentrations are approximately 75% lower than in patients with normal CYP2D6 activity. Administration of strong CYP2D6 inhibitors reduces endoxifen circulating levels to a similar extent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tamoxifen was not mutagenic in a range of in vitro and in vivo mutagenicity tests. Tamoxifen was genotoxic in some in vitro and in vivo genotoxicity tests in rodents. Gonadal tumours in mice and liver tumours in rats receiving tamoxifen have been reported in long-term studies. The clinical relevance of these findings has not been established.<br />Tamoxifen is a drug on which extensive clinical experience has been obtained. Relevant information for the prescriber is provided elsewhere in the Summary of Product Characteristics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Croscarmellose Sodium USNF<br />Gelatin Ph. Eur.<br />Lactose Ph. Eur.<br />Macrogol 300 B.P.<br />Magnesium Stearate Ph. Eur.<br />Maize Starch Ph. Eur.<br />Methylhydroxypropylcellulose Ph. Eur.<br />Titanium Dioxide Ph. Eur. (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Please refer to the outer pack.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Store in the original container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium blister pack containing 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use as directed by the prescriber.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca UK Limited,
600 Capability Green,
Luton, LU1 3LU, UK.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7th February 2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>